Aslan Pharmaceuticals announced positive data from an ongoing multicentre phase 1b/2 clinical trial of varlitinib plus gemcitabine and cisplatin, or gem/cis, in first-line biliary tract cancer, or BTC. Varlitinib in combination with gem/cis has been well tolerated in BTC patients and the data also demonstrate increased activity of varlitinib in combination with gem/cis compared to gem/cis alone. The data will be presented during a poster presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco on January 18.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.